• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Sunday, November 22, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Immune Cell Complement Regulators Are Tied to Geographic Atrophy Progression Rate

by
November 20, 2026
in Health
Reading Time: 5 mins read
0
Immune Cell Complement Regulators Are Tied to Geographic Atrophy Progression Rate

Immune Cell Complement Regulators Are Tied to Geographic Atrophy Progression Rate

Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

A prospective observational investigation conducted by clinical researchers at Zealand University Hospital in Denmark indicates that systemic levels of specific complement regulatory proteins on circulating white blood cells correlate with the progression rate of geographic atrophy secondary to age-related macular degeneration. Geographic atrophy represents an advanced, non-exudative stage of age-related macular degeneration that causes irreversible loss of visual acuity through the progressive deterioration of retinal pigment epithelial cells, overlying photoreceptors, and underlying choriocapillaris architecture. While the complement cascade constitutes a pivotal branch of the innate immune defense against invasive microbial threats, uncontrolled complement activation has been implicated across diverse ocular degenerative processes. The newly reported clinical data suggest that altered cellular expression of complement regulatory proteins, most notably the protective cell-surface inhibitor CD59, is directly linked to how swiftly atrophic retinal lesions enlarge across the human retina over time.

To evaluate these immunological associations, researchers enrolled 143 total individuals over a 22-month recruitment window from the hospital’s Department of Ophthalmology. Following screening and specific protocol-defined exclusions, the primary analytical cohort comprised 130 participants, consisting of 85 confirmed geographic atrophy patients without prior or concurrent neovascular age-related macular degeneration and 45 ophthalmologically healthy control volunteers aged 60 years or older. Exclusions were applied to eliminate potential confounding influences on systemic inflammatory markers, removing individuals with active malignancy, ongoing infectious or systemic inflammatory diseases, concurrent immunomodulatory therapies, active cigarette smoking habits, baseline serum C-reactive protein concentrations exceeding 16 milligrams per liter, or prior intraocular anti-vascular endothelial growth factor injections. During follow-up, four individuals developed neovascular disease, three received cancer diagnoses, three died, one demonstrated elevated C-reactive protein, and two were lost to monitoring, leaving 85 geographic atrophy patients for complete serial analysis.

Measurement of disease progression relied upon high-resolution blue fundus autofluorescence imaging obtained at study baseline and following a minimum monitoring interval of seven months, yielding a mean observation span of 13.1 months across a total range from 7 to 22 months. Quantitative delineation of geographic atrophy lesion boundaries was executed on 30-degree field-of-view images utilizing semi-automated MATLAB image processing software. To verify assessment precision, two independent evaluators performed blinded measurements, establishing an intergrader agreement intraclass correlation coefficient greater than 0.99 with a 95 percent confidence interval extending between 0.99 and 1.0. For each individual eye, annual lesion expansion was calculated in square millimeters per year, followed by a mathematical square root transformation to reduce the statistical dependency of lesion expansion rates upon baseline atrophy dimensions, which averaged 6.71 square millimeters across the cohort at baseline examination.

Using square root progression rates, the investigators stratified the geographic atrophy cohort into tertiles, establishing lower and upper boundary thresholds at 0.174 millimeters per year and 0.306 millimeters per year, respectively. Patients whose enlargement rates fell within the lowest tertile were classified as slow progressors, exhibiting a mean transformed progression of 0.10 millimeters per year, while individuals within the highest tertile were categorized as fast progressors, demonstrating an average transformed rate of 0.48 millimeters per year. Across the entire cohort before transformation, the mean unadjusted lesion progression rate was 1.45 square millimeters per year, with a median of 1.03 square millimeters per year, figures that conform closely to historical natural history data documented in larger longitudinal macular degeneration studies.

Immunophenotyping of peripheral venous blood collected at baseline was performed via flow cytometry within four hours of venipuncture to quantify cell-surface complement regulatory protein presentation. Following erythrocyte lysis and standardized washing procedures, 100,000 singlet leukocyte events per sample were analyzed using fluorochrome-conjugated monoclonal antibodies directed against cell lineage markers and regulatory proteins. The research team specifically quantified the cell-surface presence of CD59, an essential protective inhibitor preventing the terminal assembly of the lytic membrane attack complex, and CD35, also known as complement receptor 1, which accelerates convertase decay and functions as a cofactor for Factor I-mediated cleavage of C3b and C4b. Gating strategies isolated monocyte subsets based on CD14 and CD16 markers alongside T lymphocyte subsets delineated by CD4 and CD8 expression.

The flow cytometric evaluations demonstrated that individuals affected by geographic atrophy exhibited a significantly lower proportion of CD59-expressing CD4-positive T lymphocytes compared to healthy controls, with median values of 96.3 percent against 98.1 percent, respectively. A corresponding significant decrement in CD59 positivity was identified on CD8-positive cytotoxic T cells, where geographic atrophy patients showed a median of 44.3 percent relative to 56.2 percent observed in healthy individuals. Crucially, when comparing patient groups stratified by lesion expansion rate, fast progressors displayed a significantly lower median proportion of CD59-positive CD8-positive T cells at 42.0 percent compared to 48.5 percent in slow progressors, yielding a statistically significant difference with a p-value of 0.025.

In parallel to T-cell measurements, the study identified altered regulatory protein presentation within circulating myeloid populations. The overall proportion of classical monocytes expressing CD35 was significantly elevated among patients suffering from geographic atrophy relative to control participants, registering at a median of 2.67 percent compared to 1.71 percent among healthy volunteers. CD35 on human monocytes serves prominent immune-adherence and phagocytosis-promoting roles, mediating the binding and clearance of complement-opsonized cellular debris. The authors hypothesized that increased CD35 representation on classical monocytes might reflect a compensatory counter-regulatory mechanism or an augmented physiological requirement for phagocytic clearance driven by persistent background overactivation of early cascade components.

Genotyping analyses performed on extracted leukocyte genomic DNA evaluated two primary genetic polymorphisms extensively associated with age-related maculopathy susceptibility: complement factor H variant rs1061170 and age-related maculopathy susceptibility 2 variant rs10490924. When geographic atrophy patients were grouped according to complement factor H genotype, individuals carrying the high-risk CC or CT alleles demonstrated a significantly greater proportion of CD59-positive classical monocytes, registering a median of 5.88 percent compared to 4.70 percent in carriers of the low-risk homozygous TT genotype, with a p-value of 0.044. In contrast, stratification by the ARMS2 rs10490924 polymorphism showed no statistically significant differences in either CD35 or CD59 proportions across leukocyte subsets, and complement factor H variants showed no correlation with T-cell regulatory protein expression.

Multivariable regression testing confirmed that the observed immunological differences between geographic atrophy patients and unaffected control subjects were independent of potential confounding clinical covariates, including body mass index, arterial hypertension, hypercholesterolemia, diagnosed cardiovascular conditions, and type-2 diabetes mellitus. Additionally, while CD59 expression on CD8-positive T cells exhibited an age dependency among healthy controls with a p-value of 0.015, no statistically significant age correlation was detected within the geographic atrophy cohort itself. These findings reinforce that systemic leukocyte complement regulatory expression patterns reflect distinct pathophysiological disease manifestations rather than broad metabolic or demographic variations.

The study authors contextualized these peripheral leukocyte observations alongside existing therapeutic and pathological evidence. Although the US Food and Drug Administration has approved the C3 inhibitor pegcetacoplan and the C5 inhibitor avacincaptad pegol to reduce lesion growth in geographic atrophy, clinical benefit remains modest, emphasizing the ongoing necessity for novel therapeutic targets. In this context, experimental gene-therapy approaches utilizing adeno-associated viral vectors to express soluble CD59 have entered clinical evaluation to preserve retinal integrity. However, the researchers emphasized clear limitations within their investigation, highlighting its observational design, which precludes establishing direct causality between peripheral leukocyte regulator levels and retinal tissue loss. Furthermore, the cohort featured a modest sample of sixteen homozygous low-risk complement factor H carriers, alongside voluntary referral recruitment that may introduce patient selection bias. Consequently, further investigations are required to establish whether complement regulatory proteins can function as clinical prognostic biomarkers or actionable drug targets.

Subject of Research: Association between peripheral leukocyte complement regulatory proteins and geographic atrophy progression rate

Article Title: Complement regulatory proteins are associated with progression rate of geographic atrophy secondary to age-related macular degeneration

Article References: Villarruel Hinnerskov, J. M., Nielsen, M. K., Thomsen, A. K., Steffensen, M. A., Honoré, B., Vorum, H., Nissen, M. H., & Sørensen, T. L. (2026). Complement regulatory proteins are associated with progression rate of geographic atrophy secondary to age-related macular degeneration. Immunity & Ageing, 23(1), Article 11. https://doi.org/10.1186/s12979-026-00562-y

Image Credits: AI Generated

DOI: 10.1186/s12979-026-00562-y

Keywords: geographic atrophy, age-related macular degeneration, complement system, CD59, CD35, complement regulatory proteins, membrane attack complex, CD8 positive T cells, classical monocytes, CFH rs1061170, ARMS2 rs10490924, fundus autofluorescence, retinal degeneration, ophthalmology, flow cytometry, alternative pathway, prospective study

News Source: Ophelia Keating. (November 20, 2026). Immune Cell Complement Regulators Are Tied to Geographic Atrophy Progression Rate. Scienmag.

Tags: Age-related macular degenerationalternative pathwayARMS2 rs10490924CD35CD59CD8-positive T cellsCFH rs1061170classical monocytescomplement regulatory proteinscomplement systemflow cytometryfundus autofluorescencegeographic atrophymembrane attack complexOphthalmologyprospective studyretinal degeneration
Share12Tweet7Share2ShareShareShare1

Related Posts

Ribociclib shows promise for specific recurrent endometrial cancer subtypes in clinical trial

Ribociclib shows promise for specific recurrent endometrial cancer subtypes in clinical trial

November 22, 2026
EPHRIN-B2-Based CAR-T Cells Demonstrate In Vitro Activity Against Brain Tumors

EPHRIN-B2-Based CAR-T Cells Demonstrate In Vitro Activity Against Brain Tumors

November 22, 2026

Machine Learning Predicts Long-Term Vestibular Schwannoma Response to Radiosurgery

November 22, 2026

Marine Compound HDN2398 Inhibits Influenza A by Blocking Viral NS1 Functions

November 22, 2026

POPULAR NEWS

  • Meta-Analysis Finds Maize-Legume Intercropping Improves Yield and Stability in Sub-Saharan Africa

    Meta-Analysis Finds Maize-Legume Intercropping Improves Yield and Stability in Sub-Saharan Africa

    29 shares
    Share 12 Tweet 7
  • Ribociclib shows promise for specific recurrent endometrial cancer subtypes in clinical trial

    29 shares
    Share 12 Tweet 7
  • EPHRIN-B2-Based CAR-T Cells Demonstrate In Vitro Activity Against Brain Tumors

    29 shares
    Share 12 Tweet 7
  • Machine Learning Predicts Long-Term Vestibular Schwannoma Response to Radiosurgery

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Farm Data Predicts Barn Ammonia but Fails Prospective Time-Aware Testing

Meta-Analysis Finds Maize-Legume Intercropping Improves Yield and Stability in Sub-Saharan Africa

Ribociclib shows promise for specific recurrent endometrial cancer subtypes in clinical trial

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 89 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.